Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

NCT00471133 | Completed Phase 1

• 1 other identifier: 07-003
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence. In this study, the vaccine will be administered intramuscularly using a device that applies brief electrical fields to the tissue at the site of injection (a technique known as electroporation). It is expected that this device will improve the delivery of the vaccine. This study is being performed to determine if this procedure can be administered safely and if it is capable of inducing immune responses to the vaccine.

Conditions

Melanoma (Skin); Intraocular Melanoma

Keywords

melanoma; DNA vaccine; tyrosinase; electroporation

Outcome Measures

Primary Outcomes (1)

• Evaluate the safety and feasibility of electroporation mediated intramuscular delivery of a mouse tyrosinase plasmid DNA vaccine in patients with stage IIB, IIC, III, or IV melanoma.

  one year

Secondary Outcomes (2)

• Assess patients with measurable tumor for evidence of anti-tumor response following immunization.

  6 months

• Assess the magnitude and frequency of tyrosinase specific immunologic responses in the immunized patients

  6 months

Study Arms (1)

Xenogeneic Tyrosinase

EXPERIMENTAL

Biological: Xenogeneic Tyrosinase DNA Vaccine; Device: TriGrid Delivery System for Intramuscular Electroporation

Interventions

Xenogeneic Tyrosinase DNA Vaccine BIOLOGICAL

Xenogeneic Tyrosinase

TriGrid Delivery System for Intramuscular Electroporation DEVICE

Xenogeneic Tyrosinase

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must have documented, histologically confirmed malignant melanoma, American Joint Commission on Cancer (AJCC) Stage IIB- IV. Patients with stage IIb-III disease are only eligible after standard surgical care with wide local excision and appropriate lymph node sampling. Patients with stage IIb, IIc, or III melanoma who are free of disease after surgical resection are also eligible, only if they have refused high dose Interferon-alfa (INTRON A) or have had a recurrence while on Interferon-alfa.
• Patients with choroidal melanoma may participate if they fulfill one of the following criteria: Basal diameter \>16mm; Height \>8mm or involvement of the ciliary body with tumor.
• Patients must be at least 18 years of age and must be capable of understanding the consent form and giving informed consent.
• Karnofsky Score \> 80
• Life Expectancy \> 6 months
• HLA-A1, A2, A24, or B35+ as assessed by low resolution phenotyping
• White blood cell count ≥ 2,000/mm3
• Platelet count ≥ 100,000/mm3
• Neutrophil count ≥ 1,000/mm3
• Hemoglobin ≥ 9.0 g/dL
• Serum AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Serum Bilirubin ≤ 2.0 mg/dL
• Serum Creatinine ≤ 2.0 mg/dL
• Serum Alkaline Phosphatase \< 2.5 times ULN
• Serum Creatine phosphokinase (CPK) \< 2.5 times ULN

You may not qualify if:

• Documented metastases in brain
• Clinical history of HIV, HepB, HepC, and/or HTLV I.
• Active autoimmune disease other than vitiligo
• Patients previously immunized using the tyrosinase DNA sequence, protein, or peptides.
• Systemic immunosuppressive therapy (corticosteroids, or other immunosuppressive drugs) within the previous 28 days
• Surgery and/or radiotherapy within the previous 28 days
• Chemotherapy and/or biotherapy within the previous 28 days
• Participation in an investigational study within previous 28 days
• Patients with cardiac demand pacemakers.
• Women who are pregnant or \< 3 months post partum or nursing.
• Women of child-bearing potential and sexually active men must be using appropriate contraception during the course of this study.
• Any other concurrent medical condition that in the opinion of the Principal Investigator or co-Principal Investigator's would preclude study compliance.

Sponsors & Collaborators

• Ichor Medical Systems Incorporated: lead
• Memorial Sloan Kettering Cancer Center: collaborator

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10021, United States

Location

Related Publications (1)

• Yuan J, Ku GY, Adamow M, Mu Z, Tandon S, Hannaman D, Chapman P, Schwartz G, Carvajal R, Panageas KS, Houghton AN, Wolchok JD. Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. J Immunother Cancer. 2013 Nov 18;1:20. doi: 10.1186/2051-1426-1-20. eCollection 2013.

  PMID: 24829756 DERIVED

MeSH Terms

Conditions

Melanoma; Uveal Melanoma

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases; Uveal Neoplasms; Eye Neoplasms; Eye Diseases; Uveal Diseases

Study Officials

• Jedd D. Wolchok, MD, PhD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: May 8, 2007
• First Posted: May 9, 2007
• Study Start: April 1, 2007
• Primary Completion: May 1, 2010
• Study Completion: May 1, 2010
• Last Updated: June 7, 2011

Record last verified: 2011-06

Locations

US (1)